Lagier-Tourenne, Clotilde, MD, PhD
Office Phone: 617-643-6774
Clotilde Lagier-Tourenne performs patient-oriented research to understand the molecular mechanisms driving neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and to develop therapeutic strategies. Mutations and/or cellular mislocalization of several RNA binding proteins have been identified as central components in the pathogenesis of ALS and FTD. Using innovative cellular and genomics techniques, Lagier-Tourenne’s group explores the regulatory networks between RNA binding proteins and changes in RNA expression that occur in these diseases. The team also develops cellular and animal models to uncover mechanistic insights underlying neuronal death in ALS and FTD patients with C9orf72 expansion, the most common genetic cause of these conditions. Lagier-Tourenne has established collaborations with academic and pharmaceutical partners to develop novel approaches to therapy, including RNA-targeting antisense oligonucleotides and immunotherapies for patients with ALS and FTD linked to C9orf72 expansion.
Clotilde trained as both a medical geneticist and a neuroscientist, earning her MD at the Medical School of Strasbourg, France and a PhD from the University Louis Pasteur, Strasbourg. She received further training in Medical Genetics at Columbia University, where her work focused on the identification of new genetic causes of neurological disorders. After a postdoctoral training with Dr. Don Cleveland at the Ludwig Institute for Cancer Research, she became an Assistant Professor at the University of California San Diego until 2015, when she moved to MGH. She received the Alphonse Laveran Prize, the Milton-Safenowitz Postdoctoral Fellowship from the Amyotrophic Lateral Sclerosis Association, the Muscular Dystrophy Association Career Development Award, and the Frick Foundation 2013 Award (conjointly with Dr. Luc Dupuis). In 2014, Clotilde was awarded the 6th International Medicine Paulo Gontijo Award, which recognizes the most promising scientist under the age of 40 working on ALS. Clotilde is an Associate Member of the Broad Institute of MIT and Harvard.